PL2855487T3 - Związki do leczenia chorób powiązanych z niedokrwieniem-reperfuzją - Google Patents

Związki do leczenia chorób powiązanych z niedokrwieniem-reperfuzją

Info

Publication number
PL2855487T3
PL2855487T3 PL13721085T PL13721085T PL2855487T3 PL 2855487 T3 PL2855487 T3 PL 2855487T3 PL 13721085 T PL13721085 T PL 13721085T PL 13721085 T PL13721085 T PL 13721085T PL 2855487 T3 PL2855487 T3 PL 2855487T3
Authority
PL
Poland
Prior art keywords
reperfusion
ischemia
compounds
treatment
related diseases
Prior art date
Application number
PL13721085T
Other languages
English (en)
Inventor
Antonio Guarna
Federico Cozzolino
Original Assignee
Minerva Patents S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Minerva Patents S.A. filed Critical Minerva Patents S.A.
Publication of PL2855487T3 publication Critical patent/PL2855487T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08Bridged systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00Chemistry: molecular biology and microbiology
    • Y10S435/8215Microorganisms
    • Y10S435/822Microorganisms using bacteria or actinomycetales
    • Y10S435/886Streptomyces
PL13721085T 2012-03-21 2013-03-20 Związki do leczenia chorób powiązanych z niedokrwieniem-reperfuzją PL2855487T3 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT000062A ITFI20120062A1 (it) 2012-03-21 2012-03-21 Componenti per il trattamento di malattie correlate a ischemia-riperfusione.

Publications (1)

Publication Number Publication Date
PL2855487T3 true PL2855487T3 (pl) 2017-02-28

Family

ID=46147570

Family Applications (1)

Application Number Title Priority Date Filing Date
PL13721085T PL2855487T3 (pl) 2012-03-21 2013-03-20 Związki do leczenia chorób powiązanych z niedokrwieniem-reperfuzją

Country Status (24)

Country Link
US (2) US9932352B2 (pl)
EP (1) EP2855487B1 (pl)
JP (2) JP6382791B2 (pl)
KR (2) KR20150014910A (pl)
CN (1) CN104395321B (pl)
AU (2) AU2013237021B2 (pl)
CA (1) CA2907652C (pl)
CY (1) CY1118282T1 (pl)
DK (1) DK2855487T3 (pl)
EA (1) EA033160B1 (pl)
ES (1) ES2601384T3 (pl)
HR (1) HRP20161436T1 (pl)
HU (1) HUE031535T2 (pl)
IL (1) IL234796B (pl)
IN (1) IN2014CH07744A (pl)
IT (1) ITFI20120062A1 (pl)
LT (1) LT2855487T (pl)
ME (1) ME02553B (pl)
PL (1) PL2855487T3 (pl)
PT (1) PT2855487T (pl)
RS (1) RS55337B1 (pl)
SI (1) SI2855487T1 (pl)
SM (1) SMT201700055B (pl)
WO (1) WO2013140348A1 (pl)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10531655B2 (en) 2011-12-02 2020-01-14 The Regents Of The University Of California Reperfusion protection solution and uses thereof
IT202000008125A1 (it) * 2020-04-16 2021-10-16 Minerva Srl Acidi carbossilici 3-aza-biciclo[3.2.1]ottani e loro derivati per l’uso nel trattamento di infiammazioni

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GR75910B (pl) 1981-04-21 1984-08-02 Delalande Sa
DE60042585D1 (de) 2000-02-29 2009-09-03 Univ Firenze 3-Aza-6,8-dioxabicycloÄ3.2.1Üoctane und Analoga sowie diese enthaltende kombinatorische Bibliotheken
ITFI20020107A1 (it) * 2002-06-19 2003-12-19 Antonio Guarna Composizioni farmaceutiche atte all'uso nel trattamento di patologie correlate all'azione di neutrofine e composti attivi in esse contenuti
KR20050028036A (ko) * 2002-07-18 2005-03-21 화이자 프로덕츠 인크. Ccr1 케모카인 수용체의 길항제로서 비시클릭 피페리딘유도체
WO2006015183A2 (en) * 2004-07-30 2006-02-09 Axonyx, Inc. Pharmaceutical compositions for treating disorders of the skin
EP2189462B9 (en) * 2008-11-25 2012-06-13 Universita' Degli Studi di Firenze Bicyclic peptidomimetic inhibitors of aspartyl-proteases for the treatment of infectious diseases

Also Published As

Publication number Publication date
ITFI20120062A1 (it) 2013-09-22
US20180155363A1 (en) 2018-06-07
HRP20161436T1 (hr) 2017-01-13
SMT201700055B (it) 2017-03-08
WO2013140348A1 (en) 2013-09-26
EP2855487A1 (en) 2015-04-08
JP6382791B2 (ja) 2018-08-29
CA2907652A1 (en) 2013-09-26
CN104395321A (zh) 2015-03-04
EP2855487B1 (en) 2016-08-03
AU2013237021A1 (en) 2014-11-13
CY1118282T1 (el) 2017-06-28
AU2017265037A1 (en) 2017-12-07
US9932352B2 (en) 2018-04-03
HUE031535T2 (en) 2017-07-28
KR20200049912A (ko) 2020-05-08
IN2014CH07744A (pl) 2016-07-01
KR102181346B1 (ko) 2020-11-23
LT2855487T (lt) 2016-11-25
ES2601384T3 (es) 2017-02-15
JP2018168173A (ja) 2018-11-01
ME02553B (me) 2017-02-20
AU2013237021B2 (en) 2017-08-24
SI2855487T1 (sl) 2017-05-31
RS55337B1 (sr) 2017-03-31
PT2855487T (pt) 2016-12-20
US20150080388A1 (en) 2015-03-19
EA033160B1 (ru) 2019-09-30
CN104395321B (zh) 2017-05-03
DK2855487T3 (en) 2016-12-05
JP2015514069A (ja) 2015-05-18
KR20150014910A (ko) 2015-02-09
CA2907652C (en) 2021-03-16
AU2017265037B2 (en) 2018-03-15
EA201401045A1 (ru) 2015-03-31
IL234796B (en) 2018-02-28

Similar Documents

Publication Publication Date Title
HRP20190491T1 (hr) Spojevi 1-arilkarbonil-4-oksi-piperidina korisni za liječenje neurodegenerativnih bolesti
IL237275A0 (en) Compounds for the treatment of paramoxovirus viral infections
HUE037600T2 (hu) Vegyületek és készítmények paraziták által okozott fertõzések kezelésére
GB201021103D0 (en) New compounds for the treatment of neurodegenerative diseases
HK1205502A1 (en) Compounds for the treatment of mtor pathway related diseases mtor
EP2968321A4 (en) COMPOUNDS FOR THE TREATMENT OF FIBROSIS DISEASES
HK1185874A1 (zh) 用於治療癌症的新的 -氨基- -羥基-苯甲酰胺
HK1204452A1 (en) Treatment for bone diseases
IL238592B (en) Compounds for the treatment of liver diseases
SG11201404649UA (en) Novel compounds for the treatment of dyslipidemia and related diseases
IL243637A0 (en) PPAR-sparing compounds for the treatment of metabolic diseases
PL2855475T3 (pl) Alfa-karboliny do leczenia nowotworu
IL234796B (en) Compounds for the treatment of diseases related to ischemia-reperfusion
HK1210421A1 (en) Use of pregn-4-en-20-yn-3-one for the treatment of depressive disorders -4--20--3-
IL236873A0 (en) therapeutic compounds
GB201217331D0 (en) Novel compound useful for the treatment of infectious diseases
GB201207363D0 (en) Compounds for the treatment of metabolic disorders
GB201207359D0 (en) Compounds for the treatment of metabolic disorders
GB201204645D0 (en) Treatment of disease
GB201207476D0 (en) pharmaceutical for the treatment of leishmaniasis
GB201106981D0 (en) Compounds for the treatment of clostridium difficle-associated disease